V8 Peptides — Engineered Performance
Research Library
Hexarelin and the Ghrelin Receptor GHS-R1a Explained
HexarelinGuide

Hexarelin and the Ghrelin Receptor GHS-R1a Explained

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How does hexarelin interact with GHS-R1a? Hexarelin is a synthetic hexapeptide agonist of the growth hormone secretagogue receptor GHS-R1a, the G protein-coupled receptor that was cloned in 1996 and shown in 1999 to be the receptor for ghrelin. Agonist binding in cells expressing the receptor produces intracellular signaling that is read out as calcium mobilization or inositol phosphate accumulation. Because hexarelin can also bind CD36, a response should be attributed to GHS-R1a only after receptor-negative and antagonist controls. The V8 vial is a 5 mg lyophilized powder at ≥98% HPLC. For laboratory research use only; not for human consumption.

"Hexarelin acts on the ghrelin receptor" is a sentence that hides three separate claims: that it binds the receptor, that binding activates it, and that the observed cellular response comes from that activation and not from something else. Each claim needs its own evidence. This article takes them in turn, with the history of the receptor first, then what activation looks like in a dish, then the controls that connect a response to the receptor. The peptide is supplied for laboratory research use only; nothing here is guidance for any living subject.

A receptor found by its ligands, then given a natural ligand

Synthetic GH-releasing peptides such as GHRP-6 were known to release GH well before anyone knew what they bound. Howard and colleagues solved that problem in 1996, reporting a receptor in pituitary and hypothalamus that functions in GH release and responds to the synthetic secretagogues (Howard and colleagues, 1996). Reviews in the late 1990s described it as an orphan receptor involved in pulsatile GH release (Smith and colleagues, 1999). The orphan status ended in 1999, when Kojima and colleagues purified an acylated peptide from stomach, named ghrelin, and showed it to be the natural ligand of that receptor (Kojima and colleagues, 1999).

That order of events matters for how to read old papers. Hexarelin was described as a GH-releasing hexapeptide in the mid-1990s (Ghigo and colleagues, 1994), before the receptor was cloned. Early mechanistic statements were therefore inferences from physiology. The later receptor work allowed those inferences to be tested in cells that express a single known receptor.

Three ligands, one receptor

LigandOriginSize and formPractical point in the lab
GhrelinEndogenous, from stomach28 residues with an acyl group on serine 3The acyl group is labile; handling and enzyme activity affect the active fraction
HexarelinSyntheticHexapeptide His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2No lipid group; D-residues; formula C47H58N12O6 per product page
GHRP-6 and related hexapeptidesSyntheticSix residues, same scaffoldUseful for within-class comparison; see hexarelin vs GHRP-6

The contrast between the first two rows is instructive. Ghrelin is a 28-residue hormone that needs an octanoyl group for activity. Hexarelin is a small synthetic peptide that reaches the same receptor with no lipid at all. The two do not have to share every contact point to share a receptor, and the distinct binding modes are one reason why comparative pharmacology of the class is not a trivial exercise. For comparisons across the secretagogue class, see growth hormone secretagogues vs HGH.

What activation looks like in a cell

GHS-R1a is a G protein-coupled receptor, and G proteins differ in how they connect receptors to downstream effectors depending on cell type (Wettschureck and Offermanns, 2005). Intracellular calcium flux and inositol phosphate accumulation are the usual first-line readouts for secretagogue receptors of this type, because they are fast and need no special reporter; they are conventions of the field and not claims from a single paper. The checklist below follows the order in which a laboratory would normally build confidence.

  1. Express the receptor in a cell line that lacks it and confirm expression at the surface.
  2. Measure a fast signaling readout, such as calcium flux or inositol phosphate accumulation, with a full concentration–response curve.
  3. Run a reference agonist on the same plate so potency can be expressed relative to it.
  4. Add a receptor-negative parental control to show the response needs the receptor.
  5. Add an antagonist arm, pre-incubated before the agonist, to show the response can be blocked.
  6. Test a slower readout such as receptor internalization or a transcriptional reporter, to see whether pathways agree.
ReadoutTime scaleWhat it tells youLimitation
Competition bindingMinutes to hoursAffinity at the receptorDoes not show whether binding activates
Calcium fluxSeconds to minutesAcute activation and relative potencyEndogenous receptors can also raise calcium
Inositol phosphate accumulationTens of minutesCumulative signaling through the phospholipase pathwayNeeds a stable assay window
Receptor internalizationMinutes to hoursTrafficking and desensitization behaviorRequires a tagged receptor or surface-labeling method
Reporter gene or phospho-proteinHoursDownstream pathway engagementMore steps between receptor and signal; more room for artifacts

The second site: CD36

A paper that attributes every hexarelin response to GHS-R1a is making an assumption. Bodart and colleagues proposed that the scavenger receptor CD36 mediates part of the cardiovascular action of growth hormone-releasing peptides in the heart (Bodart and colleagues, 2002), and Demers and colleagues mapped the peptide binding site on CD36 by photoaffinity cross-linking (Demers and colleagues, 2004). In white adipocytes, a GH-releasing peptide was linked to CD36 and to markers of mitochondrial biogenesis (Rodrigue-Way and colleagues, 2007).

The consequence for assay design is practical. If the cell type under study expresses CD36, a response to hexarelin could come from either receptor, or both. The cleanest way to separate them is to use cells in which each receptor can be removed independently. A cell line engineered to express only GHS-R1a answers one question; a CD36-null preparation answers the other. Using both in the same study is what makes a selectivity claim defensible.

QuestionControl that answers it
Is the response receptor-mediated at all?Parental cells without GHS-R1a
Is it GHS-R1a and not CD36?CD36-null or CD36-silenced cells with GHS-R1a still present; and the reverse
Does the antagonist block it?Antagonist pre-incubation arm with a reference agonist for comparison
Is the effect specific to hexarelin's structure?An inactive analog or scrambled sequence, matched in concentration and vehicle
Is it a vehicle artifact?Same diluent at the same final fraction, including benzyl alcohol if bacteriostatic water was used

Preparing hexarelin for receptor work

The product page lists a 5 mg vial of lyophilized powder, ≥98% by HPLC, with storage at 2–8 °C and −20 °C for long-term holding, protected from heat, moisture and light. Receptor assays are unforgiving about concentration, so the arithmetic deserves care. Stock concentration is c = m / V, with the vial mass divided by the diluent volume; serial dilutions then follow C1V1 = C2V2. The reconstitution calculator performs the conversions, and no table of ready values is given here because the right numbers depend on the assay format. Because the molecule is a small cationic peptide with two tryptophan residues, use low-binding plastic for dilute solutions, protect tubes from light and make working dilutions immediately before the plate is read. General reconstitution handling is covered in how to reconstitute a lyophilized peptide, and the match between a lot and its certificate, where one has been published, can be checked in the COA library.

Interpreting potency numbers responsibly

  • Potency is system-dependent. An EC50 depends on receptor density, coupling efficiency and the readout; two labs can differ by a large factor with the same peptide.
  • Relative potency travels better than absolute potency. Report hexarelin against a reference agonist measured in the same experiment.
  • Efficacy and potency are different. A partial agonist can have high affinity and a low maximal response; report both.
  • Desensitization changes later readings. A question as basic as whether desensitization to hexarelin occurs has been asked directly in the literature (Rahim and Shalet, 1998), so a repeated-exposure arm belongs in any study that re-applies the peptide.

What to read next

For the molecule in plain language, see what is hexarelin; for the broader summary, the hexarelin research overview. Receptor-level contrasts with other secretagogues are laid out in hexarelin vs ipamorelin and hexarelin vs GHRP-2. All material is listed in the research catalog for laboratory research use only.

Related reading

Frequently asked questions

What is GHS-R1a?

The growth hormone secretagogue receptor 1a, a G protein-coupled receptor cloned in 1996 and shown in 1999 to be the receptor for ghrelin. It is also called the ghrelin receptor.

Does hexarelin bind the ghrelin receptor?

It is characterized as an agonist of GHS-R1a. Binding is shown by competition assays in receptor-expressing cells, and activation by signaling readouts such as calcium flux.

How does hexarelin differ from ghrelin at the receptor?

Ghrelin is a 28-residue peptide with an acyl group required for activity. Hexarelin is a six-residue synthetic peptide with no lipid group, yet it acts at the same receptor.

Which assay should I run first?

Intracellular calcium flux in cells expressing GHS-R1a, with a full concentration–response curve, a reference agonist and a parental-cell control on the same plate.

Can hexarelin act through CD36 as well?

Published work links growth hormone-releasing peptides to CD36 in cardiac and adipose cells. A response in CD36-expressing cells should not be attributed to GHS-R1a without separating the two receptors.

How do I show a response is receptor-mediated?

Show that it is absent in receptor-negative cells and blocked by an antagonist that is pre-incubated before the agonist.

What does desensitization mean in this context?

Reduced signaling after repeated exposure to an agonist, typically through receptor phosphorylation and internalization. Include a repeated-exposure arm if you re-apply the peptide.

How do I calculate stock concentration?

Divide the vial mass by the diluent volume (c = m / V), then use C1V1 = C2V2 for dilutions. The reconstitution calculator does the unit conversions.

What are the hexarelin vial details?

The product page lists a 5 mg lyophilized powder, ≥98% purity by HPLC, formula C47H58N12O6, stored at 2–8 °C with −20 °C for long-term holding.

Why use low-binding tubes for dilute hexarelin?

Small cationic peptides adsorb to surfaces, and the loss is proportionally greatest at low concentration. Low-binding plastic and prompt use limit the effect.

Related reading: How Hexarelin Is Made: Solid-Phase Synthesis Basics, Hexarelin and IGF-1: What Preclinical Studies Report, Hexarelin Dose Reporting in Published Animal Studies.

References

  1. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. doi:10.1126/science.273.5277.974
  2. Smith RG, et al. A new orphan receptor involved in pulsatile growth hormone release. Trends Endocrinol Metab. 1999;10(4):128-135. doi:10.1016/s1043-2760(98)00132-5
  3. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. doi:10.1038/45230
  4. Ghigo E, et al. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab. 1994;78(3):693-698. doi:10.1210/jc.78.3.693
  5. Bodart V, Febbraio M, Demers A, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res. 2002;90(8):844-849. doi:10.1161/01.res.0000016164.02525.b4
  6. Demers A, McNicoll N, Febbraio M, et al. Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochem J. 2004;382(2):417-424. doi:10.1042/bj20040036
  7. Wettschureck N, Offermanns S. Mammalian G proteins and their cell type specific functions. Physiol Rev. 2005;85(4):1159-1204. doi:10.1152/physrev.00003.2005
  8. Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998;8(Suppl B):141-143. doi:10.1016/s1096-6374(98)80039-7

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.